Ensatinib in alK-positive Patients Undergoing Initial Treatment for Advanced Non-small Cell Lung Cancer

NCT05132218 · clinicaltrials.gov ↗

UNKNOWN

Status

180

Enrollment

OTHER

Sponsor class

Conditions

ALK Positive
NSCLC Stage IIIB
NSCLC Stage IV

Interventions

DRUG: Ensatinib

Sponsor

Peking University Cancer Hospital & Institute

Collaborators

[object Object]